Liver cancer study pits immunotherapy against targeted drugs after radioactive treatment
NCT ID NCT05620771
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This study looks at adults with advanced liver cancer who first receive a radioactive treatment called Therasphere. After that, they get either immunotherapy (atezolizumab + bevacizumab) or targeted drugs (lenvatinib or cabozantinib). The goal is to see which approach better delays cancer growth. The study is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.